Anderson-Fabry disease: Developments in diagnosis and treatment

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Mehta, A B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anderson Fabry disease; Biomarkers; Enzyme replacement therapy; Late onset; galactosidase A

Indexed keywords

ALPHA GALACTOSIDASE; BIOLOGICAL MARKER;

ENZYME REPLACEMENT; FABRY DISEASE; HOSPITALIZATION; HUMAN; METABOLISM; METHODOLOGY; REVIEW;

ALPHA-GALACTOSIDASE; BIOLOGICAL MARKERS; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; HUMANS; SEVERITY OF ILLNESS INDEX;

EID: 77649212988     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp47066     Document Type: Conference Paper

References (82)

1. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008; 105: 2812-2817. (Pubitemid 351723626)
2. Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007; 146: 77-86. (Pubitemid 351640010)
3. Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S et al. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition. Arterioscler Thromb Vasc Biol. 2006; 26: 839-844. (Pubitemid 43732160)
4. Boot RG, Renkema GH, Verhoek M, Strijland A, Bliek J, de Meulemeester TM et al. The human chitotriosidase gene. Nature of inherited enzyme deficiency. J Biol Chem. 1998; 273: 25680-25685.
5. Brown LK, Miller A, Bhuptani A, Sloane MF, Zimmerman MI, Schilero G et al. Pulmonary involvement in Fabry disease. Am J Respir Crit Care Med. 1997; 155: 1004-1010. (Pubitemid 27133416)
6. Burlina AP, Manara R, Caillaud C, Laissy JP, Severino M, Klein I et al. The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol. 2008; 255: 738-744.
7. Callegaro D, Kaimen-Maciel DR. Fabry's disease as a differential diagnosis of MS. Int MS J. 2006; 13: 27- 30.
8. Clarke JT, West ML, Bultas J, Schiffmann R. The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease. Genet Med. 2007; 9: 504-509. (Pubitemid 47282038)
9. Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldek S, Lachmann RH. Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis. 2007; 30: 943-951. (Pubitemid 50002318)
10. Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry-Smith A et al. Asystematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type I. Health Technol Assess. 2006; 10: iii-iv, ix-113.
11. Cox TM. Biomarkers in lysosomal storage diseases: a review. Acta Paediatr. 2005; 94 (Suppl 447): 39-42.
12. Cox-Brinkman J, Vedder A, Hollak C, Richfield L, Mehta A, Orteu K et al. Three-dimensional face shape in Fabry disease. Eur J Hum Genet. 2007; 15: 535-542. (Pubitemid 46681457)
13. Cybulla M, Kleber M, Walter KN, Kroeber SM, Neumann HP, Engelhardt M. Is Fabry disease associated with leukaemia? Br J Haematol. 2006; 135: 264-265.
14. Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M. Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet. 2006; 43: 347-352.
15. Desnick RJ. Fabry disease: unrecognized ESRD patients and effectiveness of enzyme replacement therapy on renal pathology and function. J Inherit Metab Dis. 2002; 25: 116.
16. Desnick RJ, Schuchman EH. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat Rev Genet. 2002; 3: 954-966. (Pubitemid 35423507)
17. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003; 138: 338-346. (Pubitemid 36205932)
18. Elleder M, Bradova V, Smid F, Budesinsky M, Harzer K, Kustermann-Kuhn B et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol. 1990; 417: 449-455. (Pubitemid 20345820)
19. Fabrazyme SPC. Summary of Product Characteristics (July 2009) - Fabrazyme.GenzymeEuropeBV; 2008.
20. Fan JQ, Ishii S. Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors. FEBS J. 2007; 274: 4962-4971. (Pubitemid 47481192)
21. Frustaci A, Chimenti C. Images in cardiovascular medicine. Cryptogenic ventricular arrhythmias and sudden death by Fabry disease: prominent infiltration of cardiac conduction tissue. Circulation. 2007; 116: 350- 351.
22. Frustaci A, Chimenti C, Ricci R, Natale L, Russo MA, Pieroni M et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactoseinfusion therapy. N Engl J Med. 2001; 345: 25-32. (Pubitemid 32634268)
23. Germain DP, Benistan K, Boutouyrie P, Mutschler C. Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease. Clin Genet. 2005; 68: 93-95. (Pubitemid 40867545)
24. Hauser AC, Gessl A, Lorenz M, Voigtlander T, Fodinger M, Sunder-Plassmann G. High prevalence of subclinical hypothyroidism in patients with Anderson-Fabry disease. J Inherit Metab Dis. 2005; 28: 715-722. (Pubitemid 41349259)
25. Hollak CE, vanWeely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 1994; 93: 1288-1292.
26. Hughes DA. Early therapeutic intervention in females with Fabry disease? Acta Paediatr. 2008; 97 (Suppl 457): 41-47. (Pubitemid 351421292)
27. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J et al. Effects of enzyme replacement therapy on the cardiomyopathy ofAnderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008; 94: 153-158. (Pubitemid 351211719)
28. Invernizzi P, Bonometti M, Turri E, Benedetti M, Salviati A.Acase of Fabry disease with central nervous system (CNS) demyelinating lesions: a double trouble? Mult Scler. 2008; 14: 1003-1006.
29. Ishii S, Chang HH, Kawasaki K, Yasuda K, Wu HL, Garman SC et al. Mutant α-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. Biochem J. 2007; 406: 285-295. (Pubitemid 47310959)
30. Kaneski CR, Moore DF, Ries M, Zirzow GC, Schiffmann R. Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease. Neurology. 2006; 67: 2045-2047. (Pubitemid 44967388)
31. Keslova-Veselikova J, Hulkova H, Dobrovolny R, Asfaw B, Poupetova H, Berna L et al. Replacement of α-galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients.Virchows Arch. 2008; 452: 651-665.
32. Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol. 2004; 15: 1323-1329. (Pubitemid 38526014)
33. Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J et al. Abiochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology. 2003; 13: 305-313. (Pubitemid 36592316)
34. Lidove O, Ramaswami U, Jaussaud R, Barbey F, Maisonobe T, Caillaud C et al. Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey. Int J Clin Pract. 2006; 60: 1053-1059.
35. Lidove O, Joly D, Barbey F, Bekri S, Alexandra JF, Peigne V et al. Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int J Clin Pract. 2007; 61: 293-302.
36. Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alfa and beta. Kidney Int. 2004; 66: 1589-1595. (Pubitemid 39298394)
37. Magage S, Lubanda JC, Susa Z, Bultas J, Karetova D, Dobrovolny R et al. Natural history of the respiratory involvement in Anderson-Fabry disease. J Inherit Metab Dis. 2007; 30: 790-799. (Pubitemid 47559892)
38. Mehta A, Hughes DA. Fabry disease. In: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle (updated February 2008). Available from http://www. genetests.org; 2008.
39. Mehta A, Lewis S, Laverey C. Treatment of lysosomal storage disorders. BMJ. 2003; 327: 462-463. (Pubitemid 37056191)
40. Mehta A, Ricci R,Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C et al. Fabry disease defined: baseline clinicalmanifestations of 366 patients in the FabryOutcome Survey. Eur J Clin Invest. 2004; 34: 236-242. (Pubitemid 38406640)
41. Mehta A, Beck M, Frustaci A, Germain DP, Pastores GM, Sunder-Plassmann G. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta. Mol Genet Metab. 2008; 95: 114-115.
42. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999; 281: 249-254. (Pubitemid 29058114)
43. Mengel E, Baron K, Kalkum G, Kampmann C, Beck M. Is there a neutralizing effect of antibodies against agalsidase alfa and agalsidase beta? Acta Paediatr. 2007; 96 (Suppl 455): 108.
44. Milligan A, Hughes D, Goodwin S, Richfield L, Mehta A. Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs. 2006; 15: 330-333.
45. Monserrat L, Gimeno-Blanes JR, Marin F, Hermida- Prieto M, Garcia-Honrubia A, Perez I et al. Prevalence of Fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2007; 50: 2399-2403. (Pubitemid 50011583)
46. Murray GJ, Anver MR, Kennedy MA, Quirk JM, Schiffmann R. Cellular and tissue distribution of intravenously administered agalsidase alfa. Mol Genet Metab. 2007; 90: 307-312. (Pubitemid 46241908)
47. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med. 1995; 333: 288-293.
48. Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int. 2003; 64: 801-807. (Pubitemid 37013815)
49. National Institute for Health and Clinical Excellence. Appraising orphan drugs.Available from: http://www. nice.org.uk/niceMedia/pdf/smt/120705item4.pdf; 2008.
50. Ohashi T, Sakuma M, Kitagawa T, Suzuki K, Ishige N, Eto Y. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol Genet Metab. 2007; 92: 271-273. (Pubitemid 47513559)
51. Papaxanthos-Roche A, Deminiere C, Bauduer F, Hocke C, Mayer G, Lacombe D. Azoospermia as a new feature of Fabry disease. Fertil Steril. 2007; 88: 212 e15- e18.
52. Parini R, Rigoldi M, Santus F, Furlan F, De Lorenzo P, Valsecchi G et al. Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson-Fabry disease: testing the effects with the Mainz Severity Score Index. Clin Genet. 2008; 74: 260-266.
53. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, vanWeely S et al. The frequency of lysosomal storage diseases in the Netherlands.HumGenet. 1999; 105: 151-156. (Pubitemid 29396979)
54. Ramaswami U. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa. Acta Paediatr. 2008; 97 (Suppl 457): 38-40. (Pubitemid 351421299)
55. Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr. 2006; 95: 86-92. (Pubitemid 43041735)
56. Replagal SPC. Summary of Product Characteristics (5 March 2008) - Replagal. Shire HGT, Danderyd, Sweden; 2008.
57. Rolfs A, Bottcher T, Zschiesche M, Morris P, Winchester B, Bauer P et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005; 366: 1794-1796. (Pubitemid 41642643)
58. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation. 2002; 105: 1407-1411. (Pubitemid 34263268)
59. Saip S, Uluduz D, ErkolG. Fabry disease mimicking multiple sclerosis. Clin Neurol Neurosurg. 2007; 109: 361-363. (Pubitemid 46441632)
60. Schaefer E, Mehta A, Gal A. Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey. Acta Paediatr. 2005; 94 (Suppl 451): 87-92.
61. Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch. 2006a; 448: 337-343. (Pubitemid 43357651)
62. Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2006b; 21: 345-354. (Pubitemid 43159987)
63. Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady RO et al. Weekly enzyme replacement therapy mayslow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol. 2007; 18: 1576-1583. (Pubitemid 46717525)
64. Schoonhoven A, Rudensky B, Elstein D, Zimran A, Hollak CE, Groener JE et al. Monitoring of Gaucher patients with a novel chitotriosidase assay. Clin Chim Acta. 2007; 381: 136-139. (Pubitemid 46719145)
65. Schreiber W, Udvardi A, Kristoferitsch W. Chronic meningitis and lacunar stroke in Fabry disease. J Neurol. 2007; 254: 1447-1449. (Pubitemid 350112316)
66. Shah JS, Hughes DA, Tayebjee MH, MacFadyen RJ, Mehta AB, Elliott PM. Extracellular matrix turnover and disease severity in Anderson-Fabry disease. J Inherit Metab Dis. 2007; 30: 88-95. (Pubitemid 46140230)
67. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet. 2006; 79: 31-40. (Pubitemid 43927374)
68. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002; 62: 1933-1946. (Pubitemid 35366149)
69. Vedder AC, Cox-Brinkman J, Hollak CE, Linthorst GE, Groener JE, Helmond MT et al. Plasma chitotriosidase in male Fabry patients: a marker for monitoring lipid-laden macrophages and their correction by enzyme replacement therapy. Mol Genet Metab. 2006; 89: 239-244. (Pubitemid 44442987)
70. Vedder AC, Linthorst GE, Houge G, Groener JE, Ormel EE, Bouma BJ et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE. 2007a; 2: 598.
71. Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis. 2007b; 30: 68-78. (Pubitemid 46140228)
72. Vedder AC, Breunig F, Donker-Koopman WE, Mills K, Young E, Winchester B et al. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab. 2008; 94: 319-325.
73. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med. 1991; 324: 395-399.
74. Whybra C, Kampmann C, Krummenauer F, Ries M, Mengel E, Miebach E et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet. 2004; 65: 299-307. (Pubitemid 38443553)
75. Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008; 93: 112-128.
76. Wraith JE. Lysosomal disorders. Semin Neonatol. 2002; 7: 75-83. (Pubitemid 34742221)
77. Young E, Mills K, Morris P, Vellodi A, Lee P, Waldek S et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr. 2005; 94 (Suppl 447): 51-54.
78. Ziegler RJ, Yew NS, Li C, Cherry M, Berthelette P, Romanczuk H et al. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirusmediated gene transfer. Hum Gene Ther. 1999; 10: 1667-1682. (Pubitemid 29328211)
79. Ziegler RJ, Li C, Cherry M, Zhu Y, Hempel D, van Rooijen N et al. Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. Hum Gene Ther. 2002; 13: 935-945. (Pubitemid 34539370)
80. Ziegler RJ, Lonning SM, Armentano D, Li C, Souza DW, Cherry M et al. AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of α-galactosidase A and the induction of immune tolerance in Fabry mice. Mol Ther. 2004; 9: 231-240. (Pubitemid 38256549)
81. Ziegler RJ, Cherry M, Barbon CM, Li C, Bercury SD, Armentano D et al. Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of α-galactosidase A. Mol Ther. 2007; 15: 492-500.
82. Zuckerman S, Lahad A, Shmueli A, Zimran A, Peleg L, Orr-Urtreger A et al. Carrier screening for Gaucher disease: lessons for low-penetrance, treatable diseases. JAMA. 2007; 298: 1281-1290. (Pubitemid 47443342)